-
AstraZeneca and Amgen get optimistic phase 3 asthma drug results — Pfizer/BioNTech begin studies for third booster dose and development of vaccine for variants — Merck KGaA in biobucks pact with Debiopharm for next-gen cancer asset See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new pageDismiss Notice
Suprep unsafe, 483's, infestations
Discussion in 'Pharma Contract Manufacturing - General Discussion' started by Anonymous, Jan 14, 2012 at 2:13 PM.
Tags:
Add Tags